Publicaciones en colaboración con investigadores/as de University of Milan (2)

2023

  1. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

    The Lancet, Vol. 401, Núm. 10371, pp. 105-117

2021

  1. Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial

    European Journal of Cancer, Vol. 148, pp. 382-394